* IRadimed Corp IRMD.OQ IRMD.O is expected to show a
rise in
quarterly revenue when it reports results on October 31 for the
period ending September 30 2024
* The Winter Springs Florida-based company is expected to
report
a 9.6% increase in revenue to $18.098 million from $16.51
million a year ago, according to the mean estimate from 2
analysts, based on LSEG data.The company's guidance on August 1
2024, for the period ended September 30, was for revenue between
$18.00 million and $18.20 million.
* LSEG's mean analyst estimate for IRadimed Corp is for
earnings
of 39 cents per share. The company's EPS guidance on August 1
2024, for the period ended September 30, was between $0.38 and
$0.41
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for IRadimed
Corp is
$60.00, above its last closing price of $52.03.
This summary was machine generated October 29 at 13:48 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)